nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

Combining Electrochemotherapy with Targeted Therapy Olaparib in vitro

verfasst von : M. Bosnjak, L. Janzic, M. Cemazar, G. Sersa

Erschienen in: 8th European Medical and Biological Engineering Conference

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Electrochemotherapy is a local tumor ablation technique with different effectiveness in different histological types of tumors. In the treatment of breast cancer metastases, the effectiveness of electrochemotherapy is among the lowest. Therefore, combined therapies are needed. The aim of our study was to combine electrochemotherapy with PARP inhibitor olaparib, which would inhibit the repair of bleomycin/cisplatin caused DNA damage and would most likely potentiate the effectiveness of electrochemotherapy. First we demonstrated the effectiveness of electrochemotherapy with bleomycin and cisplatin alone in human breast cancer cell line MCF7 in vitro. Further, we confirmed that effectiveness of electrochemotherapy could be potentiated by combining it with olaparib, but only when bleomycin was used as a cytotoxic drug.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Characteristic Waveforms for Testing of Medical Aerosol Inhalers

Nächstes Kapitel Comparison Between Conventional SQUID Based and Novel OPM Based Measuring Systems in MEG

Serša, G., Bosnjak, M., Čemažar, M., Heller, R.: Preclinical studies on electrochemotherapy. In: Miklavčič, D. (ed.) Handbook of Electroporation, pp. 1511–1525. Springer, Cham (2017). https://doi.org/10.1007/978-3-319-32886-7_45CrossRef

Miklavčič, D., Mali, B., Kos, B., Heller, R., Serša, G.: Electrochemotherapy: from the drawing board into medical practice. Biomed. Eng. Online 13, 29 (2014). https://doi.org/10.1186/1475-925X-13-29CrossRef

Mali, B., Jarm, T., Snoj, M., Sersa, G., Miklavcic, D.: Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 39, 4–16 (2013). https://doi.org/10.1016/j.ejso.2012.08.016CrossRef

Matthiessen, L.W., Keshtgar, M., Curatolo, P., Kunte, C., Grischke, E.M., Odili, J., et al.: Electrochemotherapy for breast cancer—results From the INSPECT database. Clin. Breast Cancer (2018). https://doi.org/10.1016/j.clbc.2018.03.007CrossRef

Pommier, Y., O’Connor, M.J., De Bono, J.: Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Trans. Med. (2016). https://doi.org/10.1126/scitranslmed.aaf9246CrossRef

Keung, M., Wu, Y., Vadgama, J.: PARP Inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers. J. Clin. Med. 8, 435 (2019). https://doi.org/10.3390/jcm8040435CrossRef

Cemazar, M., Sersa, G.: Recent advances in electrochemotherapy. Bioelectricity 1, 204–213 (2019). https://doi.org/10.1089/bioe.2019.0028CrossRef

Cemazar, M., Todorovic, V., Scancar, J., Lampreht, U., Stimac, M., Kamensek, U., et al.: Adjuvant TNF-α therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness. Radiol. Oncol. 49, 32–40 (2015). https://doi.org/10.1515/raon-2015-0005CrossRef

Sedlar, A., Dolinsek, T., Markelc, B., Prosen, L., Kranjc, S., Bosnjak, M., et al.: Potentiation of electrochemotherapy by intramuscular IL-12 gene electrotransfer in murine sarcoma and carcinoma with different immunogenicity. Radiol. Oncol. 46, 302–311 (2012). https://doi.org/10.2478/v10019-012-0044-9CrossRef

10.

Sersa, G., Teissie, J., Cemazar, M., Signori, E., Kamensek, U., Marshall, G., Miklavcic, D.: Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol. Immunother. 64(10), 1315–1327 (2015). https://doi.org/10.1007/s00262-015-1724-2CrossRef

11.

Cemazar, M., Ambrozic Avgustin, J., Pavlin, D., Sersa, G., Poli, A., Krhac Levacic, A., et al.: Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet. Comp. Oncol. 15, 641–654 (2017). https://doi.org/10.1111/vco.12208CrossRef

12.

Dolinsek, T., Prosen, L., Cemazar, M., Potocnik, T., Sersa, G.: Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol. Oncol. 50, 274–279 (2016). https://doi.org/10.1515/raon-2016-0042CrossRef

13.

Prevc, A., Niksic Zakelj, M., Kranjc, S., Cemazar, M., Scancar, J., Kosjek, T., et al.: Electrochemotherapy with cisplatin or bleomycin in head and neck squamous cell carcinoma: improved effectiveness of cisplatin in HPV-positive tumors. Bioelectrochemistry 123, 248–254 (2018). https://doi.org/10.1016/j.bioelechem.2018.06.004CrossRef

Titel: Combining Electrochemotherapy with Targeted Therapy Olaparib in vitro
verfasst von: M. Bosnjak
L. Janzic
M. Cemazar
G. Sersa
Verlag: Springer International Publishing
Buch: 8th European Medical and Biological Engineering Conference
Print ISBN: 978-3-030-64609-7

Electronic ISBN: 978-3-030-64610-3

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-030-64610-3_29